Direct reconstruction in CT-analogous pharmacokinetic diffuse fluorescence tomography: two-dimensional simulative and experimental validations

Xin Wang
Yanqi Zhang
Limin Zhang
Jiao Li
Zhongxing Zhou
Huijuan Zhao
Feng Gao
Direct reconstruction in CT-analogous pharmacokinetic diffuse fluorescence tomography: two-dimensional simulative and experimental validations

Xin Wang, Yanqi Zhang, Limin Zhang, Jiao Li, Zhongxing Zhou, Huijuan Zhao, and Feng Gao

Abstract. We present a generalized strategy for direct reconstruction in pharmacokinetic diffuse fluorescence tomography (DFT) with CT-analogous scanning mode, which can accomplish one-step reconstruction of the indocyanine-green pharmacokinetic-rate images within in vivo small animals by incorporating the compartmental kinetic model into an adaptive extended Kalman filtering scheme and using an instantaneous sampling dataset. This scheme, compared with the established indirect and direct methods, eliminates the interim error of the DFT inversion and relaxes the expensive requirement of the instrument for obtaining highly time-resolved date-sets of complete 360 deg projections. The scheme is validated by two-dimensional simulations for the two-compartment model and pilot phantom experiments for the one-compartment model, suggesting that the proposed method can estimate the compartmental concentrations and the pharmacokinetic-rates simultaneously with a fair quantitative and localization accuracy, and is well suitable for cost-effective and dense-sampling instrumentation based on the highly-sensitive photon counting technique.

Keywords: CT-analogous; diffuse fluorescence tomography; adaptive extended Kalman filtering; compartmental model; indocyanine green pharmacokinetics.

1 Introduction

Though the utility of enhanced static imaging based on either targeting probes (cell-surface receptor, enzyme and reporter gene, and so on) or blood-pooling agents [indocyanine green (ICG)] is obvious with respect to cancer diagnosis and image-guided surgery, recent studies have observed significant intratumor spatial heterogeneity in expression of specific molecules and/or the metabolic process of nonspecific agents, as well as variations in expression patterns and agent permeability over time, suggesting that a regional biopsy at a fixed time point may not be representative of the complete disease. In response, in vivo dynamic imaging approaches, as combined with advanced kinetic analyses, have been proposed to comprehensively examine the metabolic profiles of tumors, in addition to the cell (targeted protein) density or vascularization extent, for better identification and delineation of cancerous tissues from healthy ones. In particular, the heightened uptake of ICG, the only untargeted optical agent approved for human use, in many tumors compared with normal tissue, coined the “enhanced permeability and retention effect”, was originally observed back in the 1930s, and is now leveraged in many chemotherapy and disease characterizations. As an economical but effective way of overcoming the limitations of the conventional static diffuse fluorescence tomography (DFT), ICG-based pharmacokinetic DFT methods have been attempted by nature to provide enhanced contrast and specificity for tumor diagnosis, malignancy staging, and drug delivery assessment, and so on.

The current strategies for image reconstruction in the pharmacokinetic DFT can be categorized into indirect and direct methods: the former extracts images of the pharmacokinetic-rates by fitting the kinetic model to the time sequences of the fluorophore concentration first acquired with the conventional DFT, while the latter directly reconstructs the pharmacokinetic images by incorporating a kinetic model to the inversion procedure. For fully characterizing the ICG pharmacokinetic process, the indirect method normally requires the reconstruction of the interim ICG concentrations at not only a reasonably high temporal-resolution, but also over a large contrast variation. This presents a significant challenge to the state-of-the-art instrumentation in both the detecting sensitivity and data-acquisition mode. Although a charge-coupled-device-based system can achieve fast data-acquisition of one projection, sampling a set of the complete 360 deg projections at the required temporal-resolution (frame interval) and with enough signal-to-noise ratio (SNR) over the whole contrast range remains problematic and costly. Another adversity in the indirect method is the interim errors due to the severe ill-posedness of the DFT inversion, primarily shown as a saturating trend in the reconstruction quantitativeness with the contrast increasing. The propagation of the errors into the analysis procedure will inevitably distort the time-course, and consequently deviate the estimation of the pharmacokinetic-rates.

Many approaches have been proposed to improve the performance of the indirect strategy: Liu et al. have proposed a four-dimensional (4-D) dynamic DFT scheme with data-sets of

*Address all correspondence to: Feng Gao, E-mail: gaofeng@tju.edu.cn
simultaneous 360 deg-projections/frame and simplified the 4-D inversion with a Karhunen–Loève transformation. Zhang et al. 22 reconstructed the fluorophore concentration variation instead of the absolute fluorophore concentration through a linear approximation with data-sets of instantaneous 360 deg-projections/frame. Although the reconstruction could be achieved with an improved accuracy in the first method, the expensive requirement for fast data-acquisition remains. While for the second method, a reasonably small frame interval is requested to mitigate the deviation due to the temporally piecewise linear approximation, which also put forward a high demand for detection sensitivity which otherwise might lead to a bias in the estimation of subsequent kinetic parameters.

To overcome the inherent shortcomings of the indirect methods, the direct methods are currently under intensive investigation: A simple way is to incorporate a biexponential kinetic model into the DFT inversion to express a kinetics-to-measurement map, and directly extract the pharmacokinetics-related decaying constants from the data-sets of instantaneous 360 deg-projections/frame. 10–13 Since the accurate pharmacokinetic fundamental is lacking, the biexponential model is empirical and thus, has no direct relationship with the tissue physiology. In addition, the reconstruction is nonreal-time and computationally intensive due to simultaneous exploitation of the total data-sets. A more complex method is based on the two-compartment model for the fluorophore kinetics to construct the kinetics-to-measurement map, and successively recovers the pharmacokinetic-rates with reasonable accuracy.

2 Methods

Figure 1 shows the generalized schematic of a CT-analogous pharmacokinetic DFT, where the D detecting positions \( r_d^s \) \((d = 1, 2, \cdots, D)\) are evenly distributed on the surface of the phantom from 101.25 deg to 258.75 deg, opposite to an incidence (0 deg) at the S source positions \( r_s \) \((s = 1, 2, \cdots, S)\), at a given imaging plane, and \( N_d \) discrete detectors are employed for the projection acquisition in a multiplexing way at a sampling period of \( \Delta T \). 23 With such a configuration, \( L (= D/N_d) \) simultaneous samplings are performed to collect one complete projection, i.e., the data at all the detecting positions with regard to the illumination of one source, with the assumption that \( N_d \) is smaller than or equal to \( D \). Normally, \( P \) sets of the complete 360 deg projections are required to sufficiently cover a kinetic range of \( P \times S \times L \times \Delta T \). The
measurements are used in the normalized Born formulation of the excitation flux, \( I_e(\mathbf{r}_e, t) \), and emission flux, \( I_m(\mathbf{r}_e, t) \), as follows:24

\[
\mathbf{I}_{mb}(p, s, l) = \left[ \begin{array}{c}
I_e(\mathbf{r}_{i+1j+1, 0}, t) \\
I_e(\mathbf{r}_{i+1j+1, 1}, t) \\
\vdots \\
I_e(\mathbf{r}_{j+1i+1, 0}, t) \\
I_e(\mathbf{r}_{j+1i+1, 1}, t) 
\end{array} \right],
\]

where \( p, s = 1, 2, \ldots, P, s = 1, 2, \ldots, S \), and \( l = 1, 2, \ldots, L \) denotes the number of the complete 360 deg data-sets, source positions and samplings, respectively.

2.1 Kinetics-to-Measurement Mapping

A crucial step toward the direct extraction of the pharmacokinetic-rates is to explicitly associate the time-dependent samplings with the kinetic model. In this work, a more generalized multicompartment model is methodologically adopted that describes the mutual permeability of administrated ICG agent among the conceptually divided \( N_c \) compartments as well as its drainage out of tissue. The generalized model describes an increasingly function-detailed pharmacokinetic process; e.g., in the four-compartment model, the tissue is assumed to be composed of capillary region, interstitial fluid region, parenchymal cell region, and intracellular binding site, whereas, in the widely used two-compartment model, the interstitial fluid region, parenchymal cell region, and intracellular binding site are combined into a single compartment referred to as extra-cellular extra-vascular space (EES), and in the simplest one-compartment model, all the four compartments are merged and only the ICG drainage out of tissue is considered.1

For the generalized multicompartment model, a discrete nonlinear state-space (kinetic) model is expressed as follows, with regard to both the compartmental concentrations and the kinetics-relevant parameters:25-28

\[
\begin{align*}
\mathbf{C}(\mathbf{r}, k + 1) &= \mathbf{K}(\theta(\mathbf{r}, k)) \mathbf{C}(\mathbf{r}, k) + \mathbf{\omega}(\mathbf{r}, k) \\
\theta(\mathbf{r}, k + 1) &= \theta(\mathbf{r}, k) \\
\end{align*}
\]

Table 1 Adaptive-EKF algorithm.

Table 2 Pharmacokinetic-rates with three contrasts for simulation.

\[
\begin{array}{ccc}
\text{Target/Background (s-1)} & \text{Contrast = 4} & \text{Contrast = 3} & \text{Contrast = 2} \\
K_{pe} & 0.012/0.003 & 0.009/0.003 & 0.006/0.003 \\
K_{ps} & 0.004/0.001 & 0.003/0.001 & 0.002/0.001 \\
K_p & 0.025/0.025 & & \\
\end{array}
\]

Fig. 2 Geometric sketch of the phantom used in the simulative validations.
To obtain the kinetics-to-measurement mapping, we first define a state vector, \( \mathbf{X} = \begin{bmatrix} C_T(r_1) ; \theta_T(r_1) ; \cdots ; C_T(r_N) ; \theta_T(r_N) \end{bmatrix}^T \), to merge the compartmental concentrations and the interim kinetic parameters at all the nodes \( r_n (n = 1,2, \cdots, N) \), and then combine the spatially-resolved multicompartment model with the DFT imaging equation that maps the sequences of the concentration image to the boundary samplings. This finally results in a new kinetic model regarding \( X^{14,20,25-28} \)

\[
\begin{align*}
\mathbf{X}(k+1) &= \mathbf{A}(k)\mathbf{X}(k) + \delta(k) \\
\mathbf{I}_{nb}(k) &= \Lambda(k)\mathbf{X}(k) + \gamma(k)
\end{align*}
\]

where \( \mathbf{A} = \text{diag}[\mathbf{K}(r_1), \mathbf{I}, \mathbf{K}(r_2), \mathbf{I}, \cdots, \mathbf{K}(r_N), \mathbf{I}] \), with \( \mathbf{I} \) being an identity matrix; \( \Lambda(k) = \varepsilon \eta \ln(10)\mathbf{W}(k)\mathbf{E} \) is referred to as the kinetics-to-measurement mapping matrix, with \( \eta(=0.016) \) and \( \varepsilon(=0.013 \text{ mm}^{-1} \mu \text{M}^{-1}) \) being the quantum efficiency and extinction coefficients of ICG, \( 7,14,20 \) respectively, \( \mathbf{E} \) is the

**Fig. 3** Estimated results for three contrasts of \( K_{pe} \) (up) and \( K_{ep} \) (bottom): (a) images of the pharmacokinetic-rates by the indirect strategy, (b) images of the pharmacokinetic-rates by the direct strategy, and the X-profiles for the scenario of, and (c) contrast = 2, (d) contrast = 3, and (e) contrast = 4 of the two strategies. The black circles indicate the ideal location and size of the targets.
First, one-step ahead predictions of the state vector and the error-covariance matrix, \( \hat{x}(k|k-1) \) and \( P(k|k-1) \), are made according to their previous step \( \hat{x}(k-1) \) and \( P(k-1) \). Then the Kalman gain and the innovation sequence at the current step, \( G(k) \) and \( d(k) \), are determined, respectively, based on the two predictions, \( \hat{x}(k|k-1) \) and \( P(k|k-1) \), as well as the currently calculated the kinetics-to-measurement mapping matrix \( \Lambda(k) \). Finally, the state vector \( \hat{x}(k) \), the error-covariance matrix \( P(k) \) and the Jacobian matrix \( J(k) \) are updated for the current step, respectively, through the Kalman gain \( G(k) \) as well as a temporally varying forgetting-factor \( \lambda(k) \) that compensates the inaccuracy of the initial states and emphasizes the effect of the current data by averaging the previous innovations inside a moving window.20,29,30

### 3 Validations

To evaluate the performance of the proposed scheme, we conducted both the simulations and phantom experiments, with the former validating the theoretical feasibility while the latter demonstrated the technological effectiveness, of the method.

#### 3.1 Simulative Investigations

In the simulations, the two-compartment model (\( N_c = 2 \)) is used that has been widely-applied in the previous studies.7,14,20 Tissues in this model are assumed to be composed of plasma and the EES, and the system matrix in Eq. (3) thus reduces to

\[
K(\theta(r)) = \begin{bmatrix} r_{11}(r) & r_{12}(r) \\ r_{21}(r) & r_{22}(r) \end{bmatrix} = \exp \left( \begin{bmatrix} -K_{pe}(r) & K_p \\ K_{pe}(r) & -K_p \end{bmatrix} \Delta T \right),
\]

where \( K_{pe}, K_p \) and \( K_{pe} \) are the pharmacokinetic-rates describing the ICG leakage into the EES, the ICG drainage out of the EES, and the kinetics-to-measurement mapping matrix, respectively.
and the ICG drainage out of tissue, respectively. Correspondingly, we have \( C(r, k) = \frac{C_p(r, k)}{C_138 T} \) and \( \theta(r) = \frac{\tau_{11}(r), \tau_{12}(r), \tau_{21}(r), \tau_{22}(r)}{C_138 T} \). \( C_p(r, k) \) and \( C_e(r, k) \) denote the ICG concentration in the plasma and the EES, respectively. Note that the heterogeneity of \( K_{pe} \) and \( K_{ep} \) is the same as the physical tumor location and shape, while \( K_p \) is reasonably assumed to be constant throughout the domain.14,20

A circular tissue-emulating geometry with a 30-mm diameter is used with a circular tumor-embedded region of 6-mm diameter, centered at \((x = 5 \text{ mm}, y = 0 \text{ mm})\), as shown in Fig. 2. The absorption and reduced scattering coefficients are set to \( \mu_a = 0.035 \text{ mm}^{-1} \) and \( \mu'_s = 1.0 \text{ mm}^{-1} \), respectively, for both the excitation and emission wavelengths, i.e., 780 and 830 nm, respectively. The finite-element method (FEM) based diffusion approximation (DA) solution in 2-D is used for both the forward and inverse calculations, with a FEM mesh of 721 nodes and 1350 triangular elements.19

For the data generation, the 720-s time-course of the ICG compartmental concentrations \( C \) is first calculated according to the two-compartment model at a sampling period of \( \Delta T = 2.5 \text{ s} \) and corrupted by the Gaussian white noise with a SNR of \( \alpha_w = 40 \text{ dB} \), i.e., \( \omega(r) = K[\theta(r)]C(r)10^{-\alpha_w/20}R_N \) (\( R_N \) is the Gaussian random number) in Eq. (3), based on the pharmacokinetic parameters in Table 2. The ICG is assumed all in the plasma with a concentration of 1.0 \( \mu \text{M} \) at the starting time of \( t = 0 \text{ s} \), i.e., \( C(r, 0) = 0 \). Then the outward flux on the boundary are simulated using the FEM-DA-based forward calculation for a reference illumination-detection configuration of \( S = 16, D = 8, \) and \( N_d = 4 \), which is in agreement with the following experimental setup, and added a Gaussian noise with the SNRs of \( \alpha_s = 50 \text{ dB} \) and \( \alpha_m = 40 \text{ dB} \) for the excitation and emission, respectively.15–19

The pharmacokinetic-rate images, \( K_{pe}(r) \) and \( K_{ep}(r) \), are estimated using the proposed direct strategy by setting the noise covariance matrices in the filter to \( Q = 10^{-7}\text{I} \) and \( R = 1 \times 10^{-4}\text{I} \), and the initial pharmacokinetic-rates to 0, and are compared with the results reconstructed by the indirect strategy.14,20 To simplify the procedure, an \textit{a priori} value of \( K_p \) is empirically determined by fitting the time course of the normalized Born measurement at a fixed detection position, \( I_{0b}(k) \), and a single exponential function \( B(\exp(-K_p \Delta T k)) \).31 Figure 3 shows the estimated results for three contrasts of

---

**Fig. 5** (a) Experimental setup. (b) Phantom and imaging plane.
including the images and their X-profiles by the indirect strategy and the direct strategy. The black circles indicate the ideal location and size of the targets. As shown in Fig. 3, a good agreement between the true and the estimated images is observed in terms of the localization and size of the target. It can be found from the X-profiles that the direct strategy outperforms the indirect one in the estimation accuracy. Three metrics are introduced for quantitative assessment of the accuracy and sensitivity performances, referred to as mean square error (MSE), contrast-to-noise ratio (CNR), and quantitativeness ratio (QR),\textsuperscript{32} and one of the terms calculated for the above simulations, from which it is observed that the direct strategy achieves a lower MSE, a higher CNR, and a higher QR than the indirect one.

In addition to the pharmacokinetic-rates, the time-courses of the EES and plasma concentration images, $C_p(k)=[C_p(r_1,k),\cdots,C_p(r_M,k)]^T$ and $C_p(k)=[C_p(r_1,k),\cdots,C_p(r_M,k)]^T$, are also estimated in the procedure, giving the total concentration image of $C_T(k)=C_e(k)+C_p(k)$. Figure 4 shows the estimated average time-courses of ICG compartmental concentrations and their MSEs in the target and background regions for the scenario of contrast $=3$. It is expected that the direct estimations of the average compartmental concentrations $C_e(k)$ and $C_p(k)$, (therefore, the average total concentration $C_T(k)$), converge faster than the indirect estimations in both the target and background regions. This observation presents a reinforced validation of the superiority of the direct estimation to the indirect one.

### 3.2 Phantom Experiments

A pilot phantom experiment is conducted using the lab-equipped CW-DFT system of CT-analogous scanning mode, as shown in Fig. 5. The system uses a 780-nm diode laser (MDL300, PicoQuant), specifically suitable for the ICG excitation. The laser beam is coupled into a source fiber with a core diameter of 300 \(\mu\)m and a numerical aperture (NA) of 0.22, then collimated to impinge the boundary of the phantom. The transmitted light is collected by eight (\(D=8\)) detection fibers with a 500-\(\mu\)m core diameter and NA = 0.37, and coupled into a 8 \(\times\) 4 fiber-optic switch with its output collimated again for normal incidence to four motorized filter wheels (FW102C, Thorlabs) that house a single-bandpass interference filter (ICG-B Emitter, Semrock) each with a center wavelength of the passband 830 nm for the detection of the ICG emission. The filtered beams finally enter into four (\(N_d=4\)) PMTs.

![Fig. 6](image_url)

**Fig. 6** Experimental results estimated by the direct strategy: (a) the images of $K_p$, (b) the X-profiles of $K_p$, (c) the QRs of $K_p$, and (d) the average target concentration time-courses.
photon-counting heads (H8259-02, Hamamatsu, Japan) and are resolved by a four-channel counter at an integration time (i.e., sampling period) of $\Delta T = 1$ s. By rotating the imaging chamber at an angular interval of 22.5 deg, four ($P = 4$) complete sets of the 360 deg projections can be acquired.

A liquid phantom is used as shown in Fig. 5(b), which is made from a cylindrical polyformaldehyde chamber of 30-mm diameter filled with 1%-Intralipid as the background and a cylindrical tube of 12-mm diameter filled with a mixture of 1%-Intralipid solution and ICG (GE Healthcare) with an initial concentration of $C_0 = 8 \mu$M as the target. To simulate the simple one-compartment kinetic process in the target region, 1%-Intralipid fresh solution and the base solution are pumped into and out of the target tube, respectively, by two pumps (BT100-02, China) simultaneously working at the same flow velocity $v_p$, keeping a constant target volume of $V_0 = 5$ mL.

The system matrix in Eq. (3) reduces to $K(\theta(r)) = \tau(r) = \exp(-K_p \Delta T)$ with $K_p = -v_p/V_0$, for the one-compartment model in this scenario. Three sets of the flow velocities, i.e., $v_p = 0.0053, 0.021,$ and $0.042$ mL/s, are employed in the validation to simulate the different kinetic processes. Figure 6 shows the $K_p$ images and target concentration time-courses estimated by the proposed direct scheme. It can be found that, for all the three cases, the $K_p$ is estimated with reasonably small errors in view of the localization and size of the target, as well as approximate proportions to the expected values, as shown in Fig. 6(c). Although the estimations of the average target concentrations deviate from the expected ones, the different kinetic processes are explicitly distinguished.

4 Discussions and Conclusions

In the above validations, we have presented the quantitative comparison between the proposed direct strategy and the conventional indirect one for different kinetic contrasts, based on a cost-effective system configuration using four parallel detection channels. Essentially, optimization of the illumination-detection configuration or the sampling period in the direct strategy within the adaptive-EKF scheme might be feasible for enhancement of the methodology performance, and more importantly, for simplification of the instrumentation complexity, with a criterion of retaining a constant total time of the kinetic process.

4.1 Illumination-Detection Configuration

The performances of the proposed direct scheme are simula-
tively investigated using four different illumination-detection configurations, as listed in Table 4. All the configurations work with the aforementioned scenario with kinetic contrast

![Fig. 7 Estimated results by the direct strategy with different illumination-detection configurations in Table 4: (a) images of $K_{pe}$ (top) and $K_{ep}$ (bottom), (b) X-profiles of $K_{pe}$, and (c) X-profiles of $K_{ep}$.

Downloaded From: https://www.spiedigitallibrary.org/journals/Journal-of-Biomedical-Optics on 08 Sep 2020
Terms of Use: https://www.spiedigitallibrary.org/terms-of-use
of three, the sampling interval of $\Delta T = 2.5$ s and the SNRs of 50 dB and 40 dB for the excitation and emission, respectively. Figure 7 shows the estimated $K_{pe}$- and $K_{ep}$-images, from which it can be found that, although the three assessment metrics calculated in Table 4 quantitatively present small differences among the four reconstructions with Case 1 being overall optimized and Case 3 minimally quantitative due to complex reasons that are worthy of future identification, the images of all cases are qualitatively of the same quality. Nevertheless, it is favorable to conclude that, without evident sacrifice of the performances, the configuration in Case 2 can implement a significant reduction in the instrumentation complexity and expense by omitting the multiplexing function.

### 4.2 Sampling Period

Physically, given the efficiency of the photoelectric conversion, the SNR of the photon counting signal is proportional to the square root of the integration time. This integration time might be properly chosen for a balance between the noise level and temporal resolution of the sampling, both observably influencing the performances. Assuming fixed SNRs of $\alpha_x = 50$ dB and $\alpha_m = 40$ dB for the reference sampling period of 2.5 s, the SNRs for an arbitrary period $\Delta T$ can be simply obtained: $\alpha_x/\alpha_m(\Delta T) = \alpha_x/\alpha_m(2.5 \text{ s}) + 20 \log_{10}(\sqrt{\Delta T/2.5 \text{ s}})$. Three sampling periods, as listed in Table 5, are employed for the investigations, which are conducted for the scenario with kinetic contrast of three and the illumination-detection configuration used as Case 1 aforementioned. The pharmacokinetic-rate images, $K_{pe}$ and $K_{ep}$, estimated by the direct strategy, for the three periods ($\Delta T = 5$, 2.5, and 1.25 s), are shown in Fig. 8, and the assessment metrics are compared in Table 5. It is found that, although the smaller $\Delta T$ generates a larger dataset, the resultant MSE for $\Delta T = 2.5$ s is smallest.

<table>
<thead>
<tr>
<th>Case</th>
<th>$S$</th>
<th>$D$</th>
<th>$N_d$</th>
<th>$P$</th>
<th>$K_{pe}/K_{ep}$</th>
<th>MSE ($\times 10^{-7}$)</th>
<th>CNR</th>
<th>QR</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>16</td>
<td>8</td>
<td>8</td>
<td>16</td>
<td>27.02/4.83</td>
<td>1.64/2.16</td>
<td>0.69/0.95</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>32</td>
<td>4</td>
<td>4</td>
<td>8</td>
<td>29.09/4.97</td>
<td>1.49/2.04</td>
<td>0.68/0.97</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>32</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>28.23/4.89</td>
<td>1.29/1.83</td>
<td>0.59/0.85</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>32</td>
<td>29.99/5.31</td>
<td>1.40/1.76</td>
<td>0.65/0.90</td>
<td></td>
</tr>
</tbody>
</table>

![Fig. 8 Estimated results by the direct strategy with different sampling periods in Table 5: (a) images of $K_{pe}$ (top) and $K_{ep}$ (bottom), (b) X-profiles of $K_{pe}$, and (c) X-profiles of $K_{ep}$.](https://www.spiedigitallibrary.org/journals/Journal-of-Biomedical-Optics)
in the three cases. This manifests a sampling period of 2.5 s as
the optimal one under the assumed noise levels.

In conclusion, both the simulations and the phantom experi-
m ents reveal that the proposed direct strategy estimates the com-
partmental concentrations and the pharmacokinetic-rates with a
fair quantitative and localization accuracy. This strategy relaxes
the restrictions on the data-acquisition mode and the system
configuration, achieving a highly-sensitive and cost-effective
detection based on the photon-counting DFT with CT-scanning mode.
Future work will focus on the in vivo experiments of small ani-
mal s and exploring the optimization in term of the illumination-
detection configuration and the sampling period, and so on.

Acknowledgments
The authors acknowledge the funding supports from the National Natural Science Foundation of China (81271618,
81371602, 61475115, 61475116, 61401453, 61575140, and
81571723), and Tianjin Municipal Government of China
and the National Key R&D Program of China (2016YFB1000103)
and the National Key Project of BeiJing (2015ZX02105001–002).

References
1. K. M Tichauer et al., “Quantitative in vivo cell-surface receptor imaging
in oncology: kinetic modeling and paired-agent principles from nuclear
2. H. Mueda, “The enhanced permeability and retention (EPR) effect in
tumor vasculature: the key role of tumor-selective macromolecular
3. N. Kosaka et al., “Near infrared fluorescence-guided real-time endo-
scopic detection of peritoneal ovarian cancer boules using intravenously
5. X. Intes et al., “In vivo continuous-wave optical breast imaging
6. X. Liu et al., “Imaging of indocyanine green perfusion in mouse
7. B. Alacan et al., “Extended Kalman filtering for the modeling and
analysis of ICG pharmacokinetics in cancerous tumors using NIRS
8. B. Alacan et al., “Pharmacokinetic-rate images of indocyanine green
dynamics in rat tumors by use of diffuse optical spectroscopy with
magnetic resonance imaging coregistration,” Appl. Opt. 42, 2940–2950
(2003).
11. G. Zhang et al., “A direct method with structural priors for imaging
pharmacokinetic parameters in dynamic fluorescence molecular tomog-
12. G. Zhang et al., “Full-direct method for imaging pharmacokinetic
parameters in dynamic fluorescence molecular tomography,” Appl.
13. G. Zhang et al., “Bayesian framework based direct reconstruction of
fluorescence parametric images,” IEEE Trans. Med. Imaging 34,
14. B. Alacan and B. Yazici, “Direct reconstruction of pharmacokinetic-
rate images of optical fluorophores from NIR measurement,” IEEE
15. V. Ntziachristos et al., “Fluorescence molecular tomography resolves
16. A. B. Milstein et al., “Fluorescence optical diffusion tomography,”
17. J. Baeten et al., “Development of fluorescent materials for diffus-
en fluorescence tomography standards and phantoms,” Opt. Express
18. L. Zhang et al., “Three-dimensional strategy for time-domain fluores-
cence molecular tomography based on Laplace transforms with noise-
19. F. Gao et al., “Simultaneous fluorescence yield and lifetime tomography
from time-resolved transmittances of small-animal-sized phantom,”
20. X. Wang et al., “Performance enhancement of pharmacokinetic diffuse
fluorescence tomography by use of adaptive extended Kalman filter-
21. X. Liu et al., “4-D reconstruction for dynamic fluorescence diffuse
(2012).
22. X. Zhang et al., “Reconstruction of fluorophore concentration variation
23. X. Wang et al., “A high-sensitive diffuse fluorescence tomography
system with CT-analogous scanning mode,” Proc. SPIE 82160V
(2012).
24. V. Ntziachristos and R. Weissleder, “Experimental three-dimensional
fluorescence reconstruction of diffuse media by use of a normalized
26. S. P. Sourborn and D. L. Buckley, “Tracer kinetic modeling in MRI:
Notes in Biomathematics, Vol. 50, Springer-Verlag, Berlin, Germany
(1983).
28. J. A. Jacquez, Compartmental Analysis in Biology and Medicine:
Kinetics of Distribution of Tracer-Labeled Materials, Elsevier, New
York (1972).
29. M. Pourayoub and D. Aubry, “A strong tracking extended Kalman
31. T. Desmettre, J. M. Devoisselle, and S. Mordon, “Fluorescence prop-
ties and metabolic features of indocyanine green (ICG) as related to
32. L. Wu et al., “Enhancement of fluorescence molecular tomography
with structural-prior-based diffuse optical tomography: combating optical

Xin Wang is a PhD candidate at Tianjin University. She received her
BS and MS degrees in biomedical engineering from Tianjin University
in 2010 and 2013, respectively. Her current research interests include
fluorescence tomography and pharmacokinetic imaging, and she has
authored more than five journal papers.

Biographies for the other authors are not available.